
Early identification of treatment failure can effectively improve the success rate of antituberculosis treatment. This study aimed to construct a predictive model using radiomics based on cavity and cavity periphery to monitor the early treatment efficacy in multidrug-resistant tuberculosis (MDR-TB). We retrospectively collected data on 350 MDR-TB patients who underwent pretreatment chest computed tomography (CT) and received longer regimens from two hospitals. They were subdivided into training (252 patients from hospital 1) and testing (98 patients from hospital 2) cohorts. According to at least two consecutive sputum culture results within the early sixth months of treatment, patients were divided into high-risk and low-risk groups. Radiomics models were established based on cavity and periphery with a range of 2, 4, 6, 8, and 10 mm. A combined model fused radiomics features of cavity with the best-performing peripheral regions. The performance of these models was evaluated by the receiver operating characteristic area under the curve (AUC) and clinical decision curve analysis. The cavity model achieved AUCs of 0.858 and 0.809 in the training and testing cohort, respectively. The radiomics model based on 4 mm peripheral region showed superior performance compared to other surrounding areas with AUCs of 0.884 and 0.869 in the two cohorts. The AUCs of the combined model were 0.936 and 0.885 in the two cohorts. CT radiomics analysis integrating cavity and cavity periphery provided value in identifying MDR-TB patients at high risk of treatment failure. The optimal periphery extent was 4 mm. The cavity periphery also contains therapy-related information. Radiomics model based on cavity and 4 mm periphery is an effective adjunct to monitor early treatment efficacy for MDR-TB patients that can guide clinical decision.
Objective: To understand the characteristics of nontuberculous mycobacteria(NTM) pulmonary disease, and provide evidence for clinical diagnosis and treatment of NTM pulmonary disease. Methods: The clinical data of 93 patients with NTM pulmonary disease admitted to Beijing Chest Hospital affiliated to Capital Medical University between January 2018 and December 2019 were analyzed retrospectively. Treatment effectivenesses were compared for different treatment. Results: Among 93 patients with NTM pulmonary disease, there were 49 cases infected with Mycobacterium intracellular, 28 cases with Mycobacterium abscesses, 4 cases with Mycobacterium avium, 4 cases with Mycobacterium kansasii, 3 cases with Mycobacterium xenopi, 2 case co-infected with Mycobacterium abscesses and Mycobacterium intracellular, one case with Mycobacterium gordonii, Mycobacterium fortuitum or Mycobacterium stutzeri each. 61 patients(65.59%) had received antituberculosis treatment before the diagnosis of NTM pulmonary disease. 90(96.77%) patients had complications, of which 52(57.78%) patients had bronchiectasis, followed by 12(13.33%) patients with chronic obstructive pulmonary disease(COPD). 83 cases(89.25%) received anti-NTM treatment, and 47 cases(56.63%) completed the course of treatment among whom the success rate of the treatment of pulmonary disease with Mycobacterium avium complex was 51.85%(14/27) while the treatment success rate of Mycobacterium abscesses pulmonary disease was 76.92%(10/13). 48 cases(57.83%) had adverse drug reactions of different degrees during the treatment, and 15 cases(18.07%) discontinued the treatment. 16 patients(19.28%) were lost to follow-up. Conclusion: Mycobacterium intracellular lung disease is the most common NTM pulmonary disease. Most patients were complicated with bronchiectasis, COPD and other basic lung diseases. The clinical characteristics of NTM pulmonary disease and pulmonary tuberculosis are similar, which are easily misdiagnosed as pulmonary tuberculosis. The cure rate of NTM pulmonary disease is low, and the rate of treatment interruption and loss to follow-up is high.
结核病是全球面临的健康威胁.肺结核是结核病的主要形式,痰液是首选的诊断标本,基于痰液的细菌学或分子生物学检查已成为金标准,但这增加了无痰患者的诊断难度.支气管肺泡灌洗液、胃液等非痰标本可用于肺结核诊断,但在采集过程中存在困难和不便.舌拭子作为一种采集简便、快捷且生物安全风险较小的标本,可能成为理想的痰液替代标本类型,或用于辅助肺结核诊断的新手段.本文中,笔者强调应重视对无痰肺结核患者的诊断,并展望了舌拭子在肺结核诊断中的应用前景.
结核病是由结核分枝杆菌(Mycobacterium tuberculosis,MTB)感染引起的慢性传染性疾病,严重危害人类健康,耐药MTB的出现加剧了疾病治疗的困难.作为抵抗MTB的主要宿主细胞,巨噬细胞极化的M1型和M2型巨噬细胞两个亚群在宿主结核感染中发挥了不同的作用.巨噬细胞的极化状态与结核病的发生、进展和转归密切相关,本文对结核病相关的M1型和M2型巨噬细胞之间极化的动态平衡及所涉及的信号通路进行综述,以期为结核病疫苗的研制和有效防治提供理论依据.
In view of the new tuberculosis infection test recommended by WHO in 2022, the MTB antigen-based skin tests(TBST) for the diagnosis of tuberculosis infection, the authors sorted out the name of new varieties of the same kind that have been listed and are under research, discussed the nomenclature of such products with reference to the principles related to nomenclature of biological products in China, expected to provide discussion and reference for experts from research and development, use and regulatory departments.